Toward anticancer gold-based compounds targeting PARP-1: A new case study

A. Citta; V. Scalcon; P. Göbel; B. Bertrand; M. Wenzel; A. Folda; M. P. Rigobello; E. Meggers; A. Casini

doi:10.1039/c6ra11606j

Toward anticancer gold-based compounds targeting PARP-1: A new case study

A. Citta, V. Scalcon, P. Göbel, B. Bertrand, M. Wenzel, A. Folda, M. P. Rigobello, E. Meggers, A. Casini

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Abstract

A new gold(iii) complex bearing a 2-((2,2′-bipyridin)-5-yl)-1H-benzimidazol-4-carboxamide ligand has been synthesized and characterized for its biological properties in vitro. In addition to showing promising antiproliferative effects against human cancer cells, the compound potently and selectively inhibits the zinc finger protein PARP-1, with respect to the seleno-enzyme thioredoxin reductase. The results hold promise for the design of novel gold-based anticancer agents disrupting PARP-1 function and to be used in combination therapies.

Original language	English
Pages (from-to)	79147-79152
Number of pages	6
Journal	RSC Advances
Volume	6
Issue number	82
DOIs	https://doi.org/10.1039/c6ra11606j
State	Published - 2016
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1039/c6ra11606j

Cite this

@article{27b028b2ac2d4a55b4dd5e13488d8c92,

title = "Toward anticancer gold-based compounds targeting PARP-1: A new case study",

abstract = "A new gold(iii) complex bearing a 2-((2,2′-bipyridin)-5-yl)-1H-benzimidazol-4-carboxamide ligand has been synthesized and characterized for its biological properties in vitro. In addition to showing promising antiproliferative effects against human cancer cells, the compound potently and selectively inhibits the zinc finger protein PARP-1, with respect to the seleno-enzyme thioredoxin reductase. The results hold promise for the design of novel gold-based anticancer agents disrupting PARP-1 function and to be used in combination therapies.",

author = "A. Citta and V. Scalcon and P. G{\"o}bel and B. Bertrand and M. Wenzel and A. Folda and Rigobello, {M. P.} and E. Meggers and A. Casini",

note = "Publisher Copyright: {\textcopyright} The Royal Society of Chemistry 2016.",

year = "2016",

doi = "10.1039/c6ra11606j",

language = "English",

volume = "6",

pages = "79147--79152",

journal = "RSC Advances",

issn = "2046-2069",

publisher = "Royal Society of Chemistry",

number = "82",

}

TY - JOUR

T1 - Toward anticancer gold-based compounds targeting PARP-1

T2 - A new case study

AU - Citta, A.

AU - Scalcon, V.

AU - Göbel, P.

AU - Bertrand, B.

AU - Wenzel, M.

AU - Folda, A.

AU - Rigobello, M. P.

AU - Meggers, E.

AU - Casini, A.

PY - 2016

Y1 - 2016

N2 - A new gold(iii) complex bearing a 2-((2,2′-bipyridin)-5-yl)-1H-benzimidazol-4-carboxamide ligand has been synthesized and characterized for its biological properties in vitro. In addition to showing promising antiproliferative effects against human cancer cells, the compound potently and selectively inhibits the zinc finger protein PARP-1, with respect to the seleno-enzyme thioredoxin reductase. The results hold promise for the design of novel gold-based anticancer agents disrupting PARP-1 function and to be used in combination therapies.

AB - A new gold(iii) complex bearing a 2-((2,2′-bipyridin)-5-yl)-1H-benzimidazol-4-carboxamide ligand has been synthesized and characterized for its biological properties in vitro. In addition to showing promising antiproliferative effects against human cancer cells, the compound potently and selectively inhibits the zinc finger protein PARP-1, with respect to the seleno-enzyme thioredoxin reductase. The results hold promise for the design of novel gold-based anticancer agents disrupting PARP-1 function and to be used in combination therapies.

UR - http://www.scopus.com/inward/record.url?scp=84984698587&partnerID=8YFLogxK

U2 - 10.1039/c6ra11606j

DO - 10.1039/c6ra11606j

M3 - Article

AN - SCOPUS:84984698587

SN - 2046-2069

VL - 6

SP - 79147

EP - 79152

JO - RSC Advances

JF - RSC Advances

IS - 82

ER -

Toward anticancer gold-based compounds targeting PARP-1: A new case study

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this